Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

The latest version of Keytruda could eventually capture between 30% and 40% of the market for the original, Merck CEO Rob Davis said at the JPMorgan Healthcare Conference in San Francisco on Monday.

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks on Jim Cramer’s ...

Shares of Merck slid Tuesday in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously ... Davis on Monday at the JPMorgan Healthcare Conference in San Francisco. "That's actually new information and an acceleration from ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.48. Earnings, adjusted for one-time gains and costs, came to $1.72 per share. The results surpassed Wall Street ...

Last year, a similar lawsuit against the biotech was dismissed by a federal judge in a San Francisco court ... The deals with Merck and SFJ are an endorsement of the bempeg programme after ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. SAN FRANCISCO — For any hopes the dealmaking that started the J.P. Morgan Healthcare Conference would ...

Merck CEO Rob Davis told CNBC's Jim Cramer that ... Get top local stories in San Diego delivered to you every morning. Sign up for NBC San Diego's News Headlines newsletter. He also pointed ...

a professor at UC Law San Francisco. Such heightened risk could lead vaccine makers to raise prices or pull a product off the market, said John Grabenstein, a consultant and former Merck vaccine ...